Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Cells. 2021 Jan 21;10(2):206. doi: 10.3390/cells10020206.
Novel coronavirus (COVID-19 or 2019-nCoV or SARS-CoV-2), which suddenly emerged in December 2019 is still haunting the entire human race and has affected not only the healthcare system but also the global socioeconomic balances. COVID-19 was quickly designated as a global pandemic by the World Health Organization as there have been about 98.0 million confirmed cases and about 2.0 million confirmed deaths, as of January 2021. Although, our understanding of COVID-19 has significantly increased since its outbreak, and multiple treatment approaches and pharmacological interventions have been tested or are currently under development to mitigate its risk-factors. Recently, some vaccine candidates showed around 95% clinical efficacy, and now receiving emergency use approvals in different countries. US FDA recently approved BNT162 and mRNA-1273 vaccines developed by Pfizer/BioNTech and Moderna Inc. for emergency use and vaccination in the USA. In this review, we present a succinct overview of the SARS-CoV-2 virus structure, molecular mechanisms of infection, COVID-19 epidemiology, diagnosis, and clinical manifestations. We also systematize different treatment strategies and clinical trials initiated after the pandemic outbreak, based on viral infection and replication mechanisms. Additionally, we reviewed the novel pharmacological intervention approaches and vaccine development strategies against COVID-19. We speculate that the current pandemic emergency will trigger detailed studies of coronaviruses, their mechanism of infection, development of systematic drug repurposing approaches, and novel drug discoveries for current and future pandemic outbreaks.
新型冠状病毒(COVID-19 或 2019-nCoV 或 SARS-CoV-2)于 2019 年 12 月突然出现,至今仍困扰着全人类,不仅影响了医疗保健系统,也影响了全球社会经济平衡。世界卫生组织(WHO)迅速将 COVID-19 定为全球大流行,截至 2021 年 1 月,已确诊病例约 9800 万例,死亡病例约 200 万例。虽然自疫情爆发以来,我们对 COVID-19 的认识有了显著提高,并且已经测试或正在开发多种治疗方法和药物干预措施来减轻其风险因素。最近,一些疫苗候选物显示出约 95%的临床疗效,目前正在不同国家获得紧急使用批准。美国食品和药物管理局(FDA)最近批准了辉瑞/生物技术公司和 Moderna 公司开发的 BNT162 和 mRNA-1273 疫苗在美国紧急使用和接种。在这篇综述中,我们简要概述了 SARS-CoV-2 病毒结构、感染的分子机制、COVID-19 流行病学、诊断和临床表现。我们还根据病毒感染和复制机制,对大流行爆发后启动的不同治疗策略和临床试验进行了系统分类。此外,我们还综述了针对 COVID-19 的新型药物干预方法和疫苗开发策略。我们推测,当前的大流行紧急情况将引发对冠状病毒、其感染机制、系统药物再利用方法开发和针对当前和未来大流行的新药发现的详细研究。